Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Lung cancer, particularly non-small cell lung cancer (NSCLC), has a high mortality rate despite advancements.
• Immune checkpoint inhibitors (ICIs) have revolutionized NSCLC treatment by modulating immune responses.
• Current predictive biomarkers, like PD-L1 expression, have limitations in accuracy and reliability for ICI therapy.

Purpose of the Study:

• To review potential biomarkers for predicting response to immune checkpoint inhibitor (ICI) therapy in NSCLC.
• To address the need for improved predictive biomarkers beyond PD-L1 expression.
• To highlight biomarkers in development for better patient stratification in lung cancer treatment.

Main Methods:

• Literature review of current and emerging biomarkers for ICI therapy in NSCLC.
• Analysis of the role of programmed death-ligand 1 (PD-L1) as a predictive biomarker.
• Exploration of novel biomarkers under development and validation stages.

Main Results:

• Programmed death-ligand 1 (PD-L1) is the sole established biomarker but lacks consistent reliability.
• Several novel biomarkers are under investigation for their potential to predict ICI response in NSCLC.
• These emerging biomarkers aim to improve the classification of responders and non-responders.

Conclusions:

• There is a critical need for more robust biomarkers to guide NSCLC treatment with ICIs.
• Emerging biomarkers show promise in enhancing the prediction of treatment efficacy.
• Future research and validation of these biomarkers could significantly improve patient outcomes in lung cancer.